Lucy C. Fairclough

Prof. Lucy C. Fairclough

Life Sciences, University of Nottingham, Nottingham, UK
orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 January 2015 in Proteomics – Clinical Applications
Verified
Journal Article
Open access
PDF file
Patrick TighePatrick Tighe
Patrick Tighe
RRRichard R. Ryder
Richard R. Ryder
ITIan Todd
Ian Todd
LFLucy C. Fairclough
Lucy C. Fairclough
Multiplex immunoassays confer several advantages over widely adopted singleplex immunoassays including increased efficiency at a reduced expense, greater output per sample volume ratios and higher throughput predicating more resolute, detailed diagnostics and facilitating personalised medicine. Nonetheless, to date, relatively few protein multiplex immunoassays have been validated for in vitro diagnostics in clinical/point‐of‐care settings. This review article will outline the challenges, which must be ameliorated prior to the widespread integration of multiplex immunoassays in clinical settings: (i) biomarker validation; (ii) standardisation of immunoassay design and quality control (calibration and quantification); (iii) availability, stability, specificity and cross‐reactivity of reagents; (iv) assay automation and the use of validated algorithms for transformation of raw data into diagnostic results. A compendium of multiplex immunoassays applicable to in vitro diagnostics and a summary of the diagnostic products currently available commercially are included, along with an analysis of the relative states of development for each format (namely planar slide based, suspension and planar/microtitre plate based) with respect to the aforementioned issues.

10 October 2020 in Inflammation Research
Verified
Journal Article
Open access
PDF file
MWMaya Williams
Maya Williams
ITIan Todd
Ian Todd
LFLucy C. Fairclough
Lucy C. Fairclough
Objective and design: This systematic review aims to establish the role of CD8 + T lymphocytes in COPD.Methods: Forty-eight papers published in the last 15 years were identified for inclusion.Results: CD8 + T-cells are increased in the lungs of patients with COPD (17 studies, 16 positive) whereas in the circulation, findings were inconclusive. Activation of CD8 + T-cells was enhanced in lungs (four studies, three positive) but cell phenotype was unclear. There was substantial evidence of a higher proportion of type 1 CD8 + (Tc1) cells in COPD (11 studies, 9 positive), though the population of type 2 (Tc2) cells was also increased (5 studies, 4 positive). CD8 + T-cells in COPD exhibited greater expression of cytotoxic proteins (five studies, five positive). Studies assessed a variety of questions so evidence was insufficient to draw firm conclusions. The role of CD8 + T-cells at acute exacerbation of COPD and also their contribution to alveolar destruction can only be hypothesised at this stage.Conclusions: Not only is the number of CD8 + T-cells increased in COPD, these cells have increased capacity to exert effector functions and are likely to contribute to disease pathogenesis. Several mechanisms highlighted show promise for future investigation to consolidate current knowledge.

1 June 2010 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
JRJoanna L. Richens
Joanna L. Richens
RURichard A. Urbanowicz
Richard A. Urbanowicz
RMRebecca Metcalf
Rebecca Metcalf
JCJonathan Corne
Jonathan Corne
POPaul O’sHea
Paul O’sHea
LFLucy C. Fairclough
Lucy C. Fairclough
The focus of biomarker studies is shifting toward deciphering patterns of biomolecules as they provide a more comprehensive depiction of disease than individual biomarkers. Multiplexing technologies are crucial in deciphering such patterns, but it is essential that they are validated for reproducibility and precision to ensure accurate protein identification. Here the authors examine such properties in Cytokine Bead Array (CBA) and Luminex kits and compare concentration measurements to those obtained using enzyme-linked immunosorbent assay (ELISA). Luminex kits were found to be highly reproducible and reliable; however, CBA kits were not due to aberrant standards. Absolute cytokine concentrations were dependent on the detection kit, but correlations with ELISA were good for all technologies.

20 June 2019 in Basic & Clinical Pharmacology & Toxicology
Verified
Journal Article
Closed access
PDF file
NTNesrin Tarbiah
Nesrin Tarbiah
ITIan Todd
Ian Todd
PTPatrick J. Tighe
Patrick J. Tighe
LFLucy C. Fairclough
Lucy C. Fairclough

20 April 2010 in Clinical Science
Verified
Journal Article
Open access
PDF file
NLNina Lane
Nina Lane
RRR. Adrian Robins
R. Adrian Robins
JCJonathan Corne
Jonathan Corne
LFLucy C. Fairclough
Lucy C. Fairclough
COPD (chronic obstructive pulmonary disease) is an inflammatory disorder of the airways, which is associated with irreversible airway obstruction. The pathological hallmarks of COPD are destruction of the lung parenchyma (pulmonary emphysema), inflammation of the central airways (chronic bronchitis) and inflammation of the peripheral airways (respiratory bronchiolitis). Tobacco smoking is established as the main aetiological factor for COPD. A maladaptive modulation of inflammatory responses to inhalation of noxious particles and gases is generally accepted as being a key central pathogenic process; however, the precise regulatory mechanisms of the disease are poorly understood. Two cell types are known to be important in immune regulation, namely regulatory T-cells and the newly identified Th17 (T-helper 17) cells. Both types of cells are subsets of CD4 T-lymphocytes and modulate the immune response through secretion of cytokines, for example IL (interleukin)-10 and IL-17 respectively. The present review will begin by describing the current understanding of inflammatory cell involvement in the disease process, and then focus on the possible role of subsets of regulatory and helper T-cells in COPD.

1 May 2013 in Methods
Verified
Journal Article
Closed access
PTPaddy Tighe
Paddy Tighe
ONOla H. Negm
Ola H. Negm
ITIan Todd
Ian Todd
LFLucy C. Fairclough
Lucy C. Fairclough